	US 11,773,135 B2
	Inhibitors of NF kappa-B activity for treatment of diseases and disorders
Rajendra Sahai Bhatnagar, Burlingame, CA (US)
Filed by Rajendra Sahai Bhatnagar, Burlingame, CA (US)
Filed on Oct. 19, 2021, as Appl. No. 17/505,544.
Application 17/505,544 is a division of application No. 15/982,837, filed on May 17, 2018, granted, now 11,174,286.
Application 15/982,837 is a continuation of application No. 14/866,040, filed on Sep. 25, 2015, granted, now 10,030,048, issued on Jul. 24, 2018.
Claims priority of provisional application 62/055,982, filed on Sep. 26, 2014.
Prior Publication US 2022/0106359 A1, Apr. 7, 2022
Int. Cl. C07K 5/10 (2006.01); C07K 5/083 (2006.01); C07K 7/06 (2006.01); A61K 38/00 (2006.01)

CPC C07K 5/10 (2013.01) [C07K 5/0806 (2013.01); C07K 7/06 (2013.01); A61K 38/00 (2013.01)]

16 Claims

1. A method of treating inflammation in a patient in need thereof, comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of one or more peptides which inhibit the activity of NF KB selected from the group consisting of peptides of six to eight amino acid residues in length, wherein the peptide comprises the sequence:

Xxx-Ala-Pro-D-Glu (CORE SEQUENCE (2)),

where Xxx is selected from the group consisting of Cys, Trp, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminocaproic acid, norleucine, α-amino-2-phenylbutyric acid, α-Amino-1-naphthalenepropanoic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala.